Daniel B Yarosh, Age 702915 Shore Dr, Merrick, NY 11566

6479533, Nov 12, 2002

Dec 1, 1999

09/452585

Daniel B. Yarosh - Merrick NY

Applied Genetics Incorporated Dermatics - Freeport NY

A61K 3415

514398, 424 91

Protection of mitochondria from oxidative damage due to natural or disease processes as well as by the effects of exogenous factors such as incident sunlight, exposure via inhalation to oxidative environmental toxins, consumption of dietary oxidants, and oxidative-stress-inducing cosmetics and pharmaceuticals, radiation therapy, among others, is provided by a composition comprising L-ergothioneine, L-ergothioneine may be prepared in a cosmetically or pharmaceutically-acceptable base to form an agent for topical application to the skin, and for oral or parenteral administration. Effective application and delivery, of L-ergothioneine is enhanced by encapsulation in a liposomes, a preferred embodiment. Diagnostic methods for determining exposure and susceptibility to radiation, radical and reactive oxygen species in mammals is also provided.

6982284, Jan 3, 2006

Sep 8, 2000

10/070466

David A. Brown - Merrick NY, US
Daniel B. Yarosh - Merrick NY, US

Applied Genetics Incorporated Dermatics - Freeport NY

A61K 31/185
A61K 31/20
A61K 31/56

514577, 514169, 514560

The topical use of ursolic acid compounds to alter the lipid content of mammalian skin is disclosed. The compounds can be encapsulated in liposomes and administered in this form to the skin in, for example, a lotion or a gel. The compounds are effective in, among other things, reducing the effects of aging, photoaging, and skin atrophy, including skin atrophy resulting from the topical use of retinoids and/or steroids. Compositions comprising a ursolic acid compound in combination with another therapeutically active topical compounds, such as, a retinoid or a steroid, are also disclosed.

7094560, Aug 22, 2006

Sep 20, 2002

10/490397

Anne B. Brown - Merrick NY, US
David A. Brown - Merrick NY, US
Daniel B. Yarosh - Merrick NY, US

Applied Genetics Incorporated Dermatics - Freeport NY

C12Q 1/37
C12N 9/22

435 23, 435199

The invention provides T4 endonuclease V compositions that exhibit enhanced stability, including stability at non-refrigerated temperatures, through reduced activity of cryptic proteases. Methods for detecting cryptic protease activity and methods for reducing such activity are also provided.

7655659, Feb 2, 2010

Aug 11, 2005

11/660283

Daniel B. Yarosh - Merrick NY, US
David A. Brown - Merrick NY, US
Matthew T. Canning - East Meadow NY, US

Applied Genetics Incorporated Dermatics - Freeport NY

A61K 31/497
A61K 31/44

51425217, 514356

Compositions and methods are provided for reversing and/or inhibiting inflammation, e. g. , by inhibiting prostaglandin and/or COX-2 production, using one or more indolequinazoline alkaloids, preferably in combination with butylated hydroxytoluene. The preferred indolequinazoline alkaloids are rutaecarpine, evodiamine, and dehydroevodiamine, which are naturally found in unpurified form in the traditional Chinese medicine Wu Chu Yu made from the fruit of the herb,.

7736878, Jun 15, 2010

Jun 29, 2006

11/478293

Daniel B. Yarosh - Merrick NY, US
Leonard F. Estis - Coram NY, US
Eliyahu Kraus - Sutton MA, US

Applied Genetics Incorporated Dermatics - Freeport NY

C12N 9/24
C12N 9/00
C12N 1/20
C12N 15/00
C12P 21/06
C07H 21/04

435200, 435 691, 435183, 4352523, 4353201, 536 232

Recombinant forms of DNA sequences for CPD glycosylases, including the bacteriophage T4 gene denV, are described that are capable of expression at high levels. Active CPD glycosylases can be recovered from inclusion bodies resulting from the high expression using, for example, a homogenization process which employs stream mixing, and the active proteins can be used in, for example, topical formulations for treatment of photosensitive diseases. Stream mixing can also be used to solubilize inclusion bodies containing proteins other than CPD glycosylases.

8410156, Apr 2, 2013

Jan 30, 2009

12/362594

Daniel B. Yarosh - Merrick NY, US

ELC Management, LLC - New York NY

A01N 43/50
A01N 37/30
A01N 47/28
A01N 41/10
A61K 31/415
A61K 31/205
A61K 31/17
A61K 31/10

514398, 514556, 514709, 514580

Compositions comprising ergothioneine and a trimethylamine absorber are provided. Also provided are methods for preventing, reducing or minimizing the fishy, amine odor, due to trimethylamine, that is associated with the processing and/or storage of a preparation containing ergothioneine, by combining with the ergothioneine, during processing or prior to storage, a trimethylamine absorber in an amount sufficient to prevent the detection of any trimethylamine odor by the human nose. A method is further provided for ameliorating the methylamine odor associated with an aqueous ergothioneine-containing preparation after it has developed a fishy trimethylamine odor.

2006028, Dec 14, 2006

Aug 21, 2006

11/507213

Anne Brown - Merrick NY, US
David Brown - Merrick NY, US
Daniel Yarosh - Merrick NY, US

Applied Genetics - Freeport NY

C12N 9/22

435199000

The invention provides T4 endonuclease V compositions that exhibit enhanced stability, including stability at non-refrigerated temperatures, through reduced activity of cryptic proteases. Methods for detecting cryptic protease activity and methods for reducing such activity are also provided.

2007020, Sep 6, 2007

Jun 7, 2005

11/628678

Daniel Yarosh - Merrick NY, US
David Brown - Merrick NY, US

Applied Genetics Incorporated Dermatics - Freeport NY

C12Q 1/68
A61K 9/127
G06Q 50/00

424450000, 435006000, 705002000

Methods are disclosed for genetically counseling a person based on one or more polymorphisms in his or her genes that sensitize him or her to toxic agents. Methods are also disclosed for genetically screening a group of individuals and/or a human population, based on, for example, ethnicity, race, religion or geographic region, to identify individuals with such polymorphisms for counseling. The methods can be used to counsel a person who has not been genetically tested for polymorphisms but who might have increased risk for sensitivity to toxic agents due to his or her membership in a particular group and/or population. The methods use correlations between genotypes of polymorphic alleles in a panel of cell lines and sensitivity of the cell lines to toxic agents. As examples, the methods are used to identify genotypes of allelic forms of the genes TP53, OGG1, ERCC2, XRCC1, and NOS3 that increase sensitivity or resistance of cells to toxic agents.